Displaying drugs 1301 - 1325 of 2216 in total
PT886
PT886 is a bispecific antibody against Claudin 18.2 and cluster of differentiation 47 (CD47)
Investigational
Lecithin
A complex mixture of phospholipids, glycolipids, triglycerides, phosphatidylcholines, phosphatidylethanolamines, and phosphatidylinositols.
Experimental
Matched Mixtures name: … aspen nutrition Omega 3-6-9 ... MENAPHASE FORMULA FILM TABLET, 90 ADET …
TTP889
TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. TTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic pathway of the blood coagulation system. TTP889 has proven...
Investigational
PHE885
PHE885 is an investigational, autologous B-cell Maturation Antigen (BCMA)-directed chimeric antigen receptor (CAR)-T cell therapy.
Investigational
SKF-96365 free base
SKF-96365 is a receptor-mediated calcium entry (RMCE) inhibitor structurally different from other calcium antagonists.
Investigational
H3B-8800
H3B-8800 is a novel spliceosome inhibitor developed by H3 Biomedicine . It offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome inhibitors, such as the pladienolide analogue E7107, show no such preferential targeting . H3B-8800 was granted orphan drug status by the FDA in August 2017 and...
Investigational
Belrestotug
Belrestotug is under investigation in clinical trial NCT05565378 (A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/metastatic Non-small-cell Lung Cancer).
Investigational
Trotabresib
Trotabresib is an oral, potent, and reversible inhibitor of the epigenetic target bromodomain and extra-terminal (BET) proteins.
Investigational
SNX-2112
SNX-2112 is a heat shock protein 90 (Hsp90) inhibitor.
Investigational
Matched Description: … SNX-2112 is a heat shock protein 90 (Hsp90) inhibitor.[A253137] …
REP8839
REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).
Investigational
Carlumab
Carlumab has been used in trials studying the treatment of Cancer and Prostate Cancer.
Investigational
Withdrawn
Pemtumomab
Pemtumomab is a murine monoclonal antibody radiolabeled with Yttrium-90. It targets the mucin 1 (MUC1) protein.
Investigational
Matched Description: … Pemtumomab is a murine monoclonal antibody radiolabeled with Yttrium-90. …
9CUAB30
9 Cuab30 has been used in trials studying the treatment and prevention of HER2/Neu Positive, HER2/Neu Negative, No Evidence of Disease, Estrogen Receptor Negative, and estrogen receptor positive, among others.
Investigational
Matched Description: … 9 Cuab30 has been used in trials studying the treatment and prevention of HER2/Neu Positive, HER2/Neu …
BC9KBY85WY
Investigational
PG-530742
PG-530742 selectively inhibits certain matrix metalloproteinases that have been implicated in the cartilage degradation that occurs in osteoarthritis. By inhibiting these MMPs, it potentially limits cartilage degradation and disease progression. Studies are currently assessing the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis.
Investigational
CP-122721
CP-122721, neurokinin 1 (NK1) antagonist is developed by Pfizer to treat depression, emesis, and inflammatory diseases including asthma and irritable bowel syndrome.
Investigational
Tanespimycin
Tanespimycin, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90). It is developed for the treatment of several types of cancer, solid tumors or chronic myelogenous leukemia.
Investigational
Matched Iupac: … tetramethyl-20,22-dioxo-19-[(prop-2-en-1-yl)amino]-2-azabicyclo[16.3.1]docosa-1(21),2,4,6,10,18-hexaen-9- …
Matched Description: … manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 …
Matched Description: … manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 …
Enokizumab
A humanized immunoglobulin G1k anti-interleukin-9 mAb.
Investigational
Matched Description: … A humanized immunoglobulin G1k anti-interleukin-9 mAb. …
Molybdate Mo-99
Experimental
Andecaliximab
Andecaliximab is a monoclonal antibody directed against matrix metallopeptidase 9 (MMP9). Andecaliximab is under investigation in clinical trial NCT03631836 (Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma).
Investigational
Matched Description: … Andecaliximab is a monoclonal antibody directed against matrix metallopeptidase 9 (MMP9). ... clinical trial NCT03631836 (Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 …
CTCE-9908
Investigational
Denecimig
Delpacibart is a humanized, bispecific, bivalent monoclonal antibody against coagulation factor 9.
Investigational
Matched Description: … Delpacibart is a humanized, bispecific, bivalent monoclonal antibody against coagulation factor 9. …
LYT-200
LYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9.
Investigational
Matched Description: … LYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9. …
Pexelizumab
Pexelizumab is a humanized monoclonal antibody used as an immunosuppressive drug. It is being investigated by Alexion Pharmaceuticals.
Investigational
Displaying drugs 1301 - 1325 of 2216 in total